Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01541189

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01541189
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01541189. Allocation not applicable; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
Condition
Hypertension
Intervention (Drug)
Valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01541189
Content hash
6b64b3d0759e076a3cd5fc8abb5f0340078c7072e15754638238e2baa0bfc040